Skip to content

NextSteps Intervention for Advanced Cancer Patients and Caregivers

NextSteps: A Supportive Care Program For Advanced Cancer Patients and Their Caregivers

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04885439
Enrollment
242
Registered
2021-05-13
Start date
2015-07-01
Completion date
2021-06-30
Last updated
2024-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Cancer, Lung Cancer

Brief summary

This study seeks to test the efficacy of a psychosocial intervention to empower advanced cancer patients and their caregivers and improve their quality of life (QOL). The program, called NextSTEPS, provides skills training in six domains that are central to patient and caregiver QOL: self-care, stress management, symptom management, effective communication, problem-solving, and social support.

Detailed description

In this study, 200 advanced cancer patients who are within one month of treatment initiation (baseline) and their caregivers will complete baseline surveys and be randomized to NextSTEPS or a usual medical care (UMC) condition. In addition to UMC, patients and caregivers in the NextSTEPS condition will each receive an intervention manual and six weekly 45-minute telephone counseling sessions with a trained interventionist. Patients and caregivers in both the NextSTEPS and UMC conditions will complete follow-up surveys at 8 weeks (primary endpoint), and 4 and 6 months post-baseline (secondary endpoints). The specific aims are to: 1. Determine the impact of NextSTEPS on patient physical and emotional QOL, palliative care utilization, and satisfaction with care relative to UMC. We hypothesize that at 8 weeks (2 months), and 4 and 6 months, patients in NextSTEPS will have less symptom burden, less emotional distress, greater palliative care utilization, and greater satisfaction with care relative to patients in UMC. 2. Determine the impact of NextSTEPS on caregiver self-care, physical and emotional QOL, and satisfaction with care. We hypothesize that at 8 weeks, and 4 and 6 months, caregivers in NextSTEPS will report more self-care, better physical QOL, less emotional distress, and greater satisfaction with care relative to caregivers in UMC. Secondary/exploratory aims and hypotheses are to: Examine the effects of the NextSTEPS intervention on Self Determination Theory (SDT) constructs. We hypothesize that NextSTEPS will enhance patient and caregiver competence, autonomy, and relatedness. Test whether the SDT constructs of competence, autonomy and relatedness mediate the effects of NextSTEPS on patient/caregiver outcomes as hypothesized. Explore whether sociodemographic (e.g., age, gender), medical (e.g., disease stage, comorbidities), and relationship factors (e.g., whether the caregiver is a spouse/partner or other family member) moderate the effects of NextSTEPS on patient/caregiver competence, autonomy, and relatedness. NextSTEPS fills an important service gap by providing education, skills training, and support to advanced cancer patients and their caregivers shortly after diagnosis. Home-based telephone delivery will facilitate dissemination and outreach. By empowering families with the skills they need to coordinate care and meet the challenges of advanced cancer together, NextSTEPS holds great promise for improving patient and caregiver QOL, and the quality of palliative and supportive care in cancer.

Interventions

BEHAVIORALNextSteps

Intervention sessions are delivered by a Masters level trained interventionist. During sessions, the interventionist will: conduct the weekly symptom screen, review content, answer questions, ensure skills mastery through homework review, and work with participants to develop action plans and identify/overcome barriers to self-care/caregiving. Patients and caregivers will receive individual calls from the interventionist for sessions 1, 2, and 3, and participate together for sessions 4, 5, and 6 via speakerphone.

Sponsors

Baylor College of Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Patient has stage 3A, 3B, or 4 NSLC or extensive stage SCLC and is within one month of treatment initiation OR patient has Stage 4 GI cancer and is within one month of treatment initiation 2. patient is spending more than 50% of time out of bed on a daily basis as measured by an ECOG Performance Status rating of level 0, 1, or 2 3. patient has stable brain metastases and no limitation on hepatic or renal function 4. patient has a spouse/partner other or close family member who he/she defines as the primary caregiver 5. patient and caregiver are age 18 years or older 6. patient and caregiver have the ability to read and understand English at a sixth grade level, as determined by ability to understand the consent form 7. patient and caregiver can provide informed consent

Exclusion criteria

1. patient or caregiver is deaf or has significant hearing impairment and thus cannot use the telephone 2. patient is currently enrolled in hospice.

Design outcomes

Primary

MeasureTime frameDescription
Patient and Caregiver Depression2 monthsPatient Reported Outcomes Measurement Information System Depression 6 item Short form
Patient and Caregiver Anxiety2 monthsPatient Reported Outcomes Measurement Information System Anxiety 6 item Short form

Secondary

MeasureTime frameDescription
Patient and Caregiver Satisfaction with Care2 months, 4 months, and 6 months20-item Family Satisfaction with Care (FAMCARE) scale
Patient Symptom Burden2 months, 4 months, and 6 monthsM D Anderson Symptom Inventory
Patient and Caregiver Depression4 and 6 monthsPatient Reported Outcomes Measurement Information System Depression 6 item Short form
Patient and Caregiver Anxiety4 and 6 monthsPatient Reported Outcomes Measurement Information System Anxiety 6 item Short form

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026